Top

European Spine Journal

Published in:

01-10-2015 | Original Article

Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage

Authors: Kun-Hui Chen, Po-Kuei Wu, Cheng-Fong Chen, Wei-Ming Chen

Published in: European Spine Journal | Issue 10/2015

Abstract

Purpose

Giant cell tumor of the sacrum is usually silent in initial stages and not diagnosed until achieving a large size. Intralesional curettage of the tumor has lower risk of neurological damage but is with high recurrence rate. Zoledronic acid-loaded cement was demonstrated to have cytotoxic effect on the cell line of giant cell tumor. This study evaluate if zoledronic acid-loaded bone cement would reduce the recurrence rate of sacral giant cell tumor after intralesional curettage.

Methods

Four patients were diagnosed as sacral giant cell tumor and received intralesional curettage with placement of zoledronic acid-loaded bone cement for adjuvant local control. The clinical records including tumor location, tumor size, complication, follow-up status, and functional outcome were analyzed retrospectively.

Results

All four patients presented with cauda equina syndrome before surgery with mean tumor volume of 472.8 cm³. With placement of zoledronic acid-loaded cement, no local recurrence was observed during the mean follow-up period of 28 months. All patients were found to have new bone regeneration on radiograph. All patients suffering from cauda equina syndrome were recovered.

Conclusions

We suggested that placement of zoledronic acid-loaded bone cement was an effective adjuvant therapy for sacral giant cell tumor following intralesional curettage.

Szendroi M (2004) Giant-cell tumour of bone. J Bone Jt Surg Br 86(1):5–12

Martin C, McCarthy EF (2010) Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J 30:69–75PubMedCentralPubMed

Bloem JL, Reidsma II (2012) Bone and soft tissue tumors of hip and pelvis. Eur J Radiol 81(12):3793–3801. doi:10.1016/j.ejrad.2011.03.101 CrossRefPubMed

Leggon RE, Zlotecki R, Reith J, Scarborough MT (2004) Giant cell tumor of the pelvis and sacrum: 17 cases and analysis of the literature. Clin Orthop Relat Res 423:196–207CrossRefPubMed

Marcove RC, Sheth DS, Brien EW, Huvos AG, Healey JH (1994) Conservative surgery for giant cell tumors of the sacrum. The role of cryosurgery as a supplement to curettage and partial excision. Cancer 74(4):1253–1260CrossRefPubMed

Althausen PL, Schneider PD, Bold RJ, Gupta MC, Goodnight JE Jr, Khatri VP (2002) Multimodality management of a giant cell tumor arising in the proximal sacrum: case report. Spine 27(15):E361–E365CrossRefPubMed

Qin LF, Peng D, Qin LH, Xu M, Fang H, Zhang Q (2014) Huge giant cell tumor of the sacrum: a case report. Oncol Lett 7(3):894–896. doi:10.3892/ol.2014.1812 PubMedCentralPubMed

Wei F, Liu X, Liu Z, Jiang L, Dang G, Ma Q, Dang L (2010) Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases. Spine 35(24):E1418–E1422. doi:10.1097/BRS.0b013e3181e7bf5a CrossRefPubMed

Guo W, Ji T, Tang X, Yang Y (2009) Outcome of conservative surgery for giant cell tumor of the sacrum. Spine 34(10):1025–1031. doi:10.1097/BRS.0b013e31819d4127 CrossRefPubMed

10.

Gille O, Oliveira Bde A, Guerin P, Lepreux S, Richez C, Vital JM (2012) Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy. Spine 37(6):E396–E399. doi:10.1097/BRS.0b013e31823ed70d CrossRefPubMed

11.

Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF (2008) Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 42(1):68–73. doi:10.1016/j.bone.2007.08.038 CrossRefPubMed

12.

Nishisho T, Hanaoka N, Endo K, Takahashi M, Yasui N (2011) Locally administered zoledronic Acid therapy for giant cell tumor of bone. Orthopedics 34(7):e312–e315. doi:10.3928/01477447-20110526-22 PubMed

13.

Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J, Cheng EY (2010) Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Jt Surg Am 92(1):162–168. doi:10.2106/JBJS.H.01679 CrossRef

14.

Wuisman P, Lieshout O, Sugihara S, van Dijk M (2000) Total sacrectomy and reconstruction: oncologic and functional outcome. Clin Orthop Relat Res 381:192–203CrossRefPubMed

15.

Ng VY, Davidson DJ, Kim EY, Pollack SM, Conrad Iii EU, Jones RL (2014) The multidisciplinary management of giant cell tumor of bone. Expert Rev Anticancer Ther 14(7):783–790. doi:10.1586/14737140.2014.901891 CrossRefPubMed

16.

Ruggieri P, Mavrogenis AF, Ussia G, Angelini A, Papagelopoulos PJ, Mercuri M (2010) Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor. Clin Orthop Relat Res 468(11):2954–2961. doi:10.1007/s11999-010-1448-8 PubMedCentralCrossRefPubMed

17.

Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res Off J Am Soc Bone Miner Res 10(10):1478–1487. doi:10.1002/jbmr.5650101008 CrossRef

18.

Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM (2004) Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 75(1):71–77. doi:10.1007/s00223-004-0120-2 CrossRefPubMed

19.

Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H (2008) Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos Biol Fate Chem 36(10):2043–2049. doi:10.1124/dmd.108.021071 CrossRefPubMed

20.

Marks KE, Nelson CL, Lautenschlager EP (1976) Antibiotic-impregnated acrylic bone cement. J Bone Jt Surg Am 58(3):358–364

21.

Moojen DJ, Hentenaar B, Charles Vogely H, Verbout AJ, Castelein RM, Dhert WJ (2008) In vitro release of antibiotics from commercial PMMA beads and articulating hip spacers. J Arthroplast 23(8):1152–1156. doi:10.1016/j.arth.2007.08.020 CrossRef

22.

Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, Jorgensen PH, Bergh P, Folleras G (2008) Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 79(1):86–93. doi:10.1080/17453670710014815 CrossRefPubMed

23.

Puri A, Agarwal M (2007) Treatment of giant cell tumor of bone: current concepts. Indian J Orthop 41(2):101–108. doi:10.4103/0019-5413.32039 PubMedCentralCrossRefPubMed

24.

Arpornchayanon O, Leerapun T (2008) Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thail Chotmaihet Thangphaet 91(10):1609–1612

25.

Chaudhary P, Khadim H, Gajra A, Damron T, Shah C (2011) Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor. Onkologie 34(12):702–704. doi:10.1159/000334549 CrossRefPubMed

Title: Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage
Authors: Kun-Hui Chen
Po-Kuei Wu
Cheng-Fong Chen
Wei-Ming Chen
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: European Spine Journal / Issue 10/2015
Print ISSN: 0940-6719
Electronic ISSN: 1432-0932
DOI: https://doi.org/10.1007/s00586-015-3978-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

Letter to the Editor concerning “Does whole-spine lateral radiograph with clavicle positioning reflect the correct cervical sagittal alignment?” by Park SM et al. (Eur Spine J 24(1):57–62)

Expert’s comment concerning “Chest wall reconstruction after en bloc Pancoast tumor resection with the use of MatrixRib and SILC Fixation systems: technical note” (Marcin Czyz, Emmanuel Addae-Boateng, Bronek M. Boszczyk)

Risk factors for major complications in surgery for hypervascular spinal tumors: an analysis of 120 cases with adjuvant preoperative embolization

Answer to the Letter to the Editor of Marco A. Marino et al. concerning “Circumferential fusion using a custom-made screw in the management of high-grade spondylolisthesis” by Jouve JL, et al. (2014) Eur Spine J; 23(Suppl. 4):S457–S462

Answer to the letter to the editor of S. Zhang et al. concerning “Continuous wound infusion of ropivacaine for the control of pain after thoracolumbar spinal surgery: a randomized clinical trial” (by Xu B, et al. (2015) Eur Spine J; 24: doi:10.1007/s00586-015-3979-x)

Malignant peripheral nerve sheath tumors presenting as spinal dumbbell tumors: clinical outcomes and characteristic imaging features